Market closed

Myriad Genetics/$MYGN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Ticker

$MYGN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Salt Lake City, United States

Employees

2,700
Website
www.myriad.com

Myriad Genetics Metrics

BasicAdvanced
$1.2B
-
-$1.30
1.94
-

$1.2B

1.94

$29.08

$12.87

995K

1.9

1.462

17.712

19.557

-31.80%

-5.35%

-16.39%

1.486

1.7

9.37

-11.407

12.15%

-61.49%

6.37%

20.08%

What the Analysts think about Myriad Genetics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.

Myriad Genetics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Myriad Genetics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Myriad Genetics News

AllArticlesVideos
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

GlobeNewsWire·6 days ago
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·7 days ago
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MYGN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Myriad Genetics stock?

Myriad Genetics (MYGN) has a market cap of $1.2B as of January 15, 2025.

What is the P/E ratio for Myriad Genetics stock?

The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of January 15, 2025.

Does Myriad Genetics stock pay dividends?

No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Myriad Genetics dividend payment date?

Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Myriad Genetics?

Myriad Genetics (MYGN) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.